Objective:To observe the anti-carcinoma and immuno-regulatory effects of shikonin derivatives.Methods:A water-soluble preparation of shikonin derivatives was prepared (designated as LE)and given by lavage (2.5～10 mg/kg daily for 10 days) to the mice inoculated with either HepA22 or S180 sarcoma. Their survival duration and the in situ tumor mass were observed. Thymus and spleen indexes of the mice were measured. The parameters for immuno-functions were detected by the routine activity assays, which included NK cytotoxicity, ConA-induced lymphocyte transformation and IL-2 production by the splenocytes of the mice. Thymic and splenic morphology of the experimental animals were microscopically examined with HE staining.Results:Both thymic and splenic indexes in the tumor-bearing mice diminished extremely compared to those of the normal control, and the immunological functions analyzed were also found obviously lowered when loaded with the transplantable carcinomas. Under light microscopy, it was surprisingly exhibited that thymus cortex was almost disappeared in the organs of tumor-bearing mice, and the germinal centers of their spleens were visibly shrunk. LE inhibited propagation of the inoculated tumors and at the same time, it amended the immunosuppresive impacts by tumor-bearing, including both structures of immune organs and the bioactivities of spleen cells.Conclusion:LE can reverse the immune damages mediated by carcinomas.

The severe fever with thrombocytopenia syndrome virus (SFTSV),a new RNA virus,was discovered in recent years,which can lead to fever,thrombocytopenia and multiple organ dysfunction.Picks is the main media A case of a SFTSV-related encephalitis diagnosed by second-generation gene sequencing was reported here.The patient had fever,disturbance of consciousness,convulsions,with thrombocytopenia and enzymatic indicators increased significantly.After active anti-virus and supportive treatment,the prognosis was good.It is our aim to suggest that,in the epidemic season,when you meet thesimilar patients like this,you should consider the possibility of SFTSV-related encephalitis.Virus nucleic acid detection and second-generation gene sequencing technology are helpful for timely diagnosis and treatment and reducing mortality of the disease.

Objective:To investigate the effect of pretreatment with butorphanol on perineal discomfort caused by intravenous injection of dexamethasone sodium phosphate.Methods:Using the method of prospective study, ninety patients undergoing elective gynecological surgery in Dalian Women And Children′s Medical Group from June to December 2021 were randomly divided into three groups: butorphanol 0.5 mg pretreatment group (group B1), butorphanol 1.0 mg pretreatment group (group B2) and normal saline control group (group C), with 30 cases in each group. Patients in groups B1 and B2 were given butorphanol 0.5 mg and 1.0 mg intravenously, respectively, prior to induction of anesthesia, while those in group C were given 0.9% sodium chloride injection. 3 minutes later, all patients in the three groups were given dexamethasone sodium phosphate injection 10 mg, and the incidence, grade and adverse reactions of their perineal discomfort symptoms were recorded.Results:The incidence of perineal discomfort and moderate perineal discomfort of patients in group B1 and group B2 was lower than that in group C: 20.00%(6/30)and 10.00%(3/30)vs. 60.00%(18/30), 3.33%(1/30)and 3.33(1/30)vs. 30.00%(10/30), with a statistically significant differences ( P<0.05). The incidence of adverse reactions such as dizziness was increased in the group B2:26.67%(8/30)and 10.00%(3/30)vs. 40.00%(12/30), with a statistically significant difference ( χ2 = 7.13, P = 0.028). Conclusions:Butorphanol 0.5 mg and 1.0 mg pretreatments are touted as effective in inhibiting perineal discomfort caused by intravenous injection of dexamethasone sodium phosphate. However, the butorphanol 0.5 mg pretreatment group have fewer adverse reactions.